Astellas Pharma Inc. (TYO:4503)
2,356.50
+29.00 (1.25%)
Aug 14, 2026, 3:30 PM JST
Astellas Pharma Revenue
Astellas Pharma had revenue of 640.91B JPY in the quarter ending June 30, 2026, with 26.71% growth. This brings the company's revenue in the last twelve months to 2.27T, up 16.93% year-over-year. In the fiscal year ending March 31, 2026, Astellas Pharma had annual revenue of 2.14T with 11.87% growth.
Revenue (ttm)
2.27T
Revenue Growth
+16.93%
P/S Ratio
1.86
Revenue / Employee
161.31M
Employees
14,099
Market Cap
4.23T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 2.14T | 226.92B | 11.87% |
| Mar 31, 2025 | 1.91T | 308.65B | 19.25% |
| Mar 31, 2024 | 1.60T | 85.05B | 5.60% |
| Mar 31, 2023 | 1.52T | 222.46B | 17.16% |
| Mar 31, 2022 | 1.30T | 46.64B | 3.73% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Otsuka Holdings | 2.62T |
| Daiichi Sankyo Company | 2.22T |
| Chugai Pharmaceutical | 1.34T |
| Kyowa Kirin | 529.80B |
| Ono Pharmaceutical | 504.41B |
| Santen Pharmaceutical | 291.84B |
| JCR Pharmaceuticals | 41.45B |
| Perseus Proteomics | 135.00M |
Astellas Pharma News
- 9 days ago - Q1 2027 Astellas Pharma Inc Earnings Presentation (Japanese) Transcript - GuruFocus
- 10 days ago - Astellas Pharma Earnings Up In Q1; Guides FY27 - Nasdaq
- 10 days ago - Astellas Pharma Quarterly report: Q1 2027 - Filings
- 10 days ago - Astellas Pharma Slides: Q1 2027 - Filings
- 2 months ago - Astellas Pharma Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 2 months ago - Astellas Pharma Slides: FY 2026 - Filings
- 2 months ago - Astellas Announces Five-Year Corporate Strategic Plan to Deliver Greater VALUE Faster for Patients and Position Itself as a Sustainable Growth Company - PRNewsWire
- 2 months ago - Astellas Pharma Slides: Investor presentation - Filings